Dyadic International (DYAI) Current Assets (2017 - 2026)
Dyadic International (DYAI) posted Current Assets of $7.7 million for Q1 2026, down 22.2% sequentially from $9.9 million in Q4 2025, and down 1.35% YoY from $7.8 million in Q1 2025.
Dyadic International (DYAI) Current Assets (2017 - 2026) Analysis & Trends
Dyadic International has reported Current Assets for 10 years, with the latest figure at $7.7 million in Q1 2026.
- Quarterly Current Assets fell 1.35% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (down 1.35% YoY) and the FY2025 annual result came in at $9.9 million, up 0.7% from the prior year.
- Current Assets eased to $7.7 million in Q1 2026 per DYAI's latest filing, from $9.9 million in the prior quarter.
- Over five years, Current Assets peaked at $16.2 billion in Q1 2022 and troughed at $7.4 million in Q2 2025.
- A 5-year average of $965.6 million and a median of $10.7 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2023: Current Assets surged 57922.59% in 2022, then tumbled 99.92% in 2023.
- Over 5 years, Current Assets stood at $13.4 million in 2022, then slumped by 39.89% to $8.1 million in 2023, then advanced by 21.82% to $9.8 million in 2024, then climbed by 0.7% to $9.9 million in 2025, then fell by 22.2% to $7.7 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $7.7 million, $9.9 million, and $11.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | 7.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.70 Mn |
| Dec 31, 2025 | 9.90 Mn |
| Sep 30, 2025 | 11.55 Mn |
| Jun 30, 2025 | 7.41 Mn |
| Mar 31, 2025 | 7.81 Mn |
| Dec 31, 2024 | 9.83 Mn |
| Sep 30, 2024 | 10.69 Mn |
| Jun 30, 2024 | 10.50 Mn |
| Mar 31, 2024 | 12.54 Mn |
| Dec 31, 2023 | 8.07 Mn |
| Sep 30, 2023 | 9.09 Mn |
| Jun 30, 2023 | 11.07 Mn |
| Mar 31, 2023 | 12.81 Mn |
| Dec 31, 2022 | 13.42 Mn |
| Sep 30, 2022 | 14.93 Mn |
| Jun 30, 2022 | 16.93 Mn |
| Mar 31, 2022 | 16.24 Bn |
| Dec 31, 2021 | 21.01 Mn |
| Sep 30, 2021 | 23.57 Mn |
| Jun 30, 2021 | 26.16 Mn |